Life Science Investing Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Life Science Investing Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Life Science Investing Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
Life Science Investing Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
Life Science Investing Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
Life Science Investing Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
Placement to Institutional and Sophisticated Investors, Appointment of Joint Broker,Issue of Equity & TVR
